Clinical pathological and prognostic significance of PD-L1 expression in lung adenocarcinoma in bioinformatics

Journal of ShanDong First Medical University&ShanDong Academy of Medical Sciences››2024,Vol. 45››Issue (4): 193-197.DOI:10.3969/j.issn.2097-0005.2024.04.001

• Basic Researches •Next Articles

Clinical pathological and prognostic significance of PD-L1 expression in lung adenocarcinoma in bioinformatics

Nana DU¹, Lu ZHANG², Jingting MIN¹, Ran AN³, Zhenghong LI²()

^1.Bengbu Medical college, Department of Basic Medical
^2.Department of Life Science
^3.Department of Public Foundation，Bengbu 233030，China

Received:2023-10-10Online:2024-04-25Published:2024-05-22
Contact:Zhenghong LI

生物信息学评估肺腺癌中PD-L1表达对临床病理和预后的意义

杜娜娜¹, 张露², 闵静婷¹, 安然³, 李正红²()

^1.蚌埠医学院，基础医学院
^2.生命科学学院
^3.公共基础学院，安徽蚌埠 233030

通讯作者:李正红
基金资助:
国家自然科学基金(81472656);安徽省重点研究与开发计划(201904a07020019);安徽省高校自然betway必威亚洲重大项目(2022AH040224);蚌埠医学院自然科学项目(Byycx23084)

Abstract

Abstract:

ObjectiveTo evaluate the clinical pathological and prognostic significance of PD-L1 expression in lung adenocarcinoma with bioinformatics， and to validate its expression and clinical pathology with immunohistochemistry.MethodsUsing the GEPIA database to analyze the quantitative expression of PD-L1 mRNA in the database， and validate it with immunohistochemical methods； Using Te Kaplan Meier Plotter to evaluate the impact of PD-L1 expression on the prognostic value of lung adenocarcinoma； Analyzing immune cell infiltration in lung adenocarcinoma with Timer2.0； Differential analysis of the expression of different subtypes of PD-L1 in lung adenocarcinoma was performed by the TCGA module of the UALCAN database.ResultsBioinformatics showed that the expression of PD-L1 in cancer tissue was significantly lower than that in normal tissue. Immunohistochemical results showed that PD-L1 was highly expressed in lung adenocarcinoma tissue， but low or no expression was observed in adjacent tissues. The expression of PD-L1 was not significantly different by age， sex， clinical stage and lymph node metastasis， but its expression was significantly correlated with the overall survival OS and first progressive survival FP of patients.ConclusionPD-L1 expression affects the survival prognosis of lung adenocarcinoma patients.

Key words:PD-L1,lung adenocarcinoma,immunohistochemical,bioinformatics

摘要：

目的利用生物信息学评估肺腺癌中PD-L1表达的临床病理和预后意义，并且用免疫组化对其表达和临床病理进行验证。方法利用GEPIA数据库分析PD-L1在数据库中mRNA的定量表达，并用免疫组化的方法进行验证；利用Te Kaplan-Meier Plotter评估PD-L1表达对肺腺癌预后价值的影响；利用Timer 2.0对肺腺癌的免疫细胞浸润进行分析；通过UALCAN数据库的TCGA模块，对不同亚型PD-L1在肺腺癌中的表达进行差异性分析。结果生物信息学显示，PD-L1在癌组织中的表达明显低于正常组织，免疫组化结果显示，PD-L1在肺腺癌癌组织中呈高表达，但在正常组织中呈低表达或不表达。PD-L1的表达在不同年龄、性别、临床分期以及淋巴结转移中差异无统计学意义，但其表达与患者的总生存期、首次进展生存期显著相关。结论PD-L1的表达与肺腺癌患者的生存预后有一定的关系。

关键词:PD-L1,肺腺癌,免疫组化,生物信息学

Nana DU, Lu ZHANG, Jingting MIN, Ran AN, Zhenghong LI. Clinical pathological and prognostic significance of PD-L1 expression in lung adenocarcinoma in bioinformatics[J]. Journal of ShanDong First Medical University&ShanDong Academy of Medical Sciences, 2024, 45(4): 193-197.

杜娜娜, 张露, 闵静婷, 安然, 李正红. 生物信息学评估肺腺癌中PD-L1表达对临床病理和预后的意义[J]. betway必威登陆网址 (betway.com )学报, 2024, 45(4): 193-197.

Figures/Tables7

分组	PD-L1病理评分
肺腺癌组织	2	6	18	36	0	62
正常组织	20	0	0	0	0	20

分组	PD-L1病理评分
肺腺癌组织	2	6	18	36	0	62
正常组织	20	0	0	0	0	20

References17

1	倪文，王羲，王奇胜，等. c-Met与GPC1在非小细胞肺癌中的表达及预后意义［J］.实用肿瘤杂志，2020，35（6）： 506.
2	Thompson RH， Gillett MD， Cheville JC， et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma［J］.Cancer，2005，104（10）： 2084.
3	Konishi J， Yamazaki K， Azuma M， et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression［J］.Clin Cancer Res，2004，10（15）： 5094.
4	Xiao JX， Bai PS， Lai BC， et al. B7 molecule mRNA expression in colorectal carcinoma［J］.World J Gastroenterol，2005，11（36）： 5655.
5	Loos M， Langer R， Schuster T， et al. Clinical significance of the costimulatory molecule B7-H1 in barrett carcinoma［J］.Ann Thorac Surg.2011，91（4）：1025.
6	Dumitru A， Dobrica EC， Croitoru A， et al. Focus on PD-1/PD-L1 as a therapeutic target in ovarian cancer［J］.Int J Mol Sci，2022，23（20）： 12067.
7	Yu H， Boyle TA， Zhou CC， et al. PD-L1 expression in lung cancer［J］.J Thorac Oncol，2016，11（7）： 964.
8	谢雯莹，贺洋，傅晓，等. 肺腺癌相关组织学特征与PD-L1表达EGFR基因突变类型的关系［J］.中国肿瘤临床，2022，49（15）： 769.
9	周荣根，王燕，陈基升，等. 非小细胞肺癌c-MET、BRAF、ROS1基因突变与临床特征的关系［J］.分子诊断与治疗杂志，2022，14（7）： 1129.
10	Thai AA， Solomon BJ， Sequist LV， et al. Lung cancer［J］.Lancet，2021，398（10299）： 535.
11	秦文华，张豪伟，杨宝军，等. NSCLC患者PD-L1表达与临床病理资料及基因突变相关性研究［J］.临床心身疾病杂志，2022，28（3）： 11.
12	Yang X， Qi C， Ji M. PD-L1 status and survival in patients with lung cancer［J］.JAMA，2019，322（8）： 783.
13	朱菊明. 肺腺癌中LAG-3， FGL1， PD-L1和CD8-+T细胞表达的相关性研究［D］. 乌鲁木齐：新疆医科大学，2022.
14	Li H， Xu Y， Wan B， et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer： a meta-analysis of 50 studies with 11，383 patients［J］.Transl Lung Cancer Res，2019，8（4）： 429.
15	Shen X， Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer： meta-analysis［J］.BMJ，2018，362： k3529.
16	Gafeer MM， Hosny Mohammed K， Ormenisan-Gherasim C， et al. Diagnostic utility of PD-L1 expression in lung adenocarcinoma： immunohistochemistry and RNA in situ hybridization［J］.Appl Immunohistochem Mol Morphol，2018，26（8）： e86.
17	Zhou SM， Zhu JF， Xu JW， et al. Anti-tumour potential of PD-L1/PD-1 post-translational modifications［J］.Immunology，2022，167（4）： 471.

[1]	Mengqi QI, Yuqin LV, Lei GAO, Jingjun ZHANG.Bioinformatics-based exploration on antiepileptic mechanism of brivaracetam[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(6): 401-407.
[2]	Yue CHEN, Jingyao SHE, Si CHEN, Ying Cao, Chunyun LIANG, Yan LU, Peijuan WANG, Zhen Gong.The expression for E2Fs in human cervical cancer and its relationship with clinical prognosis[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(3): 215-223.
[3]	Zhiyu CHEN, Han XU, Dexin YU.Prediction of ferroptosis-related genes affecting overall survival in ovarian cancer patients based on bioinformatics[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(11): 819-825.
[4]	Yongsheng HUANG, Caina HUANG, Xueling DONG, Xiuli ZHUO, Juanjuan FANG, Wenxia SONG, Yulu ZHANG, Lei YAN, Gang CHEN, Renguang LV.Derivation and validation of proteomic related individualized prognostic signatures of bladder urothelial carcinoma[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(1): 15-23.
[5]	Wen XU, Yuqin LV, Lei GAO, Jingjun ZHANG.Study on the antiepileptic mechanism of oxcarbazepine based on multi-group data[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(5): 327-334.
[6]	Wenchao BU, Xianzhi ZENG, Yunqian GUAN, Siyuan XIE, Shixin CHEN, Tingbing TANG, Mingguo CAO.Expression and bioinformatics analysis of SOCS gene family in hepatocellular carcinoma[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(10): 740-747.
[7]	Yuqin Lv, Lei Gao, Wen Xu, Menqi Qi, Jingjun Zhang.Analysis of biological pathways and PPI network related to the differential seizure frequency of temporal lobe epilepsy[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(7): 508-515.